October 14, 2024 01:43 PM EDT
Deals
Pharma

Bausch + Lom­b's stock ris­es fol­low­ing re­port of po­ten­tial bid from pri­vate eq­ui­ty firms TPG and Black­stone

Katherine Lewin

News Reporter

Pri­vate eq­ui­ty firms TPG and Black­stone are work­ing on a po­ten­tial deal to buy Brent Saun­ders-led eye care com­pa­ny Bausch + Lomb, the Fi­nan­cial Times …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Two GSK tri­als with long-act­ing drug in chron­ic rhi­nos­i­nusi­tis hit pri­ma­ry end­points

Pfiz­er de­tails re­sults from failed Phase 3 tri­al of Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py 

No­var­tis ends mid-stage IPF tri­al, will keep test­ing drug in PAH

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

No­vo Nordisk files 18 law­suits against GLP-1 com­pounders in 44 days

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times